Advaxis Announces Notice of Allowance of US Patent for ADXS-HPV Immunotherapy

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a US Patent titled “Compositions and Methods for Treatment of Cervical Cancer.” This patent specifically protects the use of the Advaxis HPV construct for the treatment of late stage cervical cancer, an unmet medical need for which this agent is currently being evaluated in 2 Phase II clinical trials, two of which are in recurrent metastatic cervical cancer, one in India and one in collaboration with the Gynecologic Oncology Group of the National Cancer Institute in the US.

Once issued, this patent will provide a new 17+ year patent cycle for Advaxis’ lead compound.

This patent establishes ADXS-HPV as a method of treatment for late stage cervical cancer in human patients using a recombinant Listeria strain comprised of a fusion of HPV E7 antigen and an N-terminal fragment of an LLO protein.

This patent also protects ADXS-HPV in various physical formulations, including a dried formulation that is stable at room temperature.

The subject matter of this patent is based on the work of Dr. Yvonne Paterson and Dr. John Rothman and is assigned to both the University of Pennsylvania and Advaxis. Together, Advaxis and the University of Pennsylvania hold over 70 approved patents and pending patent applications for composition of matter and methods of use.

About Advaxis, Inc.

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live attenuated Listeria monocytogenes (Lm) that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to Lm to the cancer itself.

ADXS-HPV, Advaxis’ first construct to reach the clinic is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer) with over 130 patients dosed to date. Over fifteen (15) distinct constructs are in various stages of development, either developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. For more information please visit: | Facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.


Advaxis, Inc.
Diana Moore
Director, Investor Relations & Business Development
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Infectious Diseases  Pharmaceutical  Consumer  General Health  Men